Global Diabetes Devices (BGM Devices/Insulin Delivery) Markets Report 2021: Market Size is Expected to Reach $44.6 Billion by 2028 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Diabetes Devices Market Size, Share & Trends Analysis Report by Type (BGM Devices, Insulin Delivery Devices), by Distribution Channel, by End-use (Hospitals, Homecare), by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

The global diabetes devices market size is expected to reach USD 44.6 billion by 2028, registering a CAGR of 6.6%

The market is driven by factors such as increasing incidence of diabetes, technological advancements, and innovative product launches. Increasing adoption of advanced diabetes management solutions in developing region, government policies, and rising medical tourism are some of the major factors contributing to the market growth.

Furthermore, rising government initiatives to spread awareness about diabetes and increasing R&D expenditure of major players are the factors expected to boost the market growth.

According to a study published on National Center for Biotechnology Information (NCBI), global health expenditure on diabetes is expected to reach USD 490 billion in 2030 from 376 billion in 2010. Obesity, sedentary lifestyle, and fast food culture are some of the factors expected to have significant impact on the market growth. According to Harvard T.H. Chan School of Public Health, U.S. has the highest rates of obesity and it is expected to increase up to 50% by 2030.

In addition, increasing number of new market players, who focus on patient convenience with the help of artificial intelligence technology, are also transforming the market. They are leveraging technological advancements to improve diabetes care solutions like CGM devices, non-invasive insulin delivery systems, and digital diabetes management platforms.

For instance, in December 2017, Companion Medical Launched Inpen, its first smart insulin pen system in the U.S. It is the only FDA-approved device that can combine insulin injector pen with a smart app.

Diabetes Devices Market Report Highlights

• North America accounted for the largest share in 2019, in terms of revenue, owing to favorable reimbursement policies, presence of key players, and frequent product launches
• By product, the insulin delivery devices segment accounted for the largest market share and is also expected to grow at the fastest rate
• In the Blood Glucose Monitoring (BGM) segment, self-monitoring devices dominated the market owing to their low cost and high usage
• In Self-monitoring of Blood Glucose (SMBG) devices, testing strips segment dominated the market while blood glucose meters are expected to grow at a significant pace owing to high adoption and technological advancements
• In the Continuous Glucose Monitoring (CGM) devices segment, transmitters accounted for the largest share owing to high cost of devices and high usage
• In insulin delivery devices, pens segment dominated the market since it is easy to carry, easy to use, and has low cost as compared to other delivery devices
• By distribution channel, hospital pharmacy segment dominated the market owing to rise in sales of diabetes devices in these pharmacies
• By end use, hospital segment accounted for the largest market share owing to improving healthcare infrastructure due to rising investment

The leading players present in the diabetes devices market are

• Medtronic
• Abbott
• Ascensia Diabetes Care Holdings AG
• Dexcom, Inc.
• F. Hoffmann-La Roche Ltd.
• Sanofi
• Novo Nordisk A/S
• Insulet Corporation
• Ypsomed
• Valeritas, Inc

Market Variables, Trends & Scope

Market Lineage Outlook

• Parent market outlook
• Ancillary market outlook

User Perspective Analysis

• Consumer behavior analysis
• Market influencer analysis

Regulatory Framework

Market Driver Analysis

• Growing prevalence of obesity and diabetes
• Technological Innovations & Product Advancements
• Growing focus on diabetes Care
• Untapped opportunities in developing economies

Market Restraint Analysis

• Stringent Regulatory Policies and Regulations
• High cost of devices

Diabetes Devices Market Analysis Tools

• Industry Analysis - Porter's
• PESTEL Analysis

Major Deals & Strategic Alliances Analysis

• Joint Ventures
• Mergers & Acquisitions
• Licensing and Partnership
• Technology collaborations
• Strategic Divestments

For more information about this report visit https://www.researchandmarkets.com/r/q2z43e

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900